LAC9 Antibody

What is LAC9 protein and why is it studied using antibodies?

LAC9 protein is a transcriptional regulator found in Kluyveromyces lactis (formerly known as Candida sphaerica), a yeast species commonly used in biotechnology research. It functions as a regulatory protein involved in transcriptional control mechanisms. Researchers use antibodies to detect, quantify, and study LAC9 protein to understand its role in gene expression regulation and metabolic pathways in yeast. The LAC9 Antibody specifically recognizes this protein, enabling researchers to track its presence, abundance, and potential modifications across various experimental conditions. This approach provides insights into transcriptional networks that would be challenging to study through other methodological approaches .

What are the key specifications of commercially available LAC9 Antibody?

LAC9 Antibody is available as a polyclonal antibody raised in rabbits against a recombinant Kluyveromyces lactis LAC9 protein. It is supplied in liquid form as a non-conjugated IgG antibody that has undergone antigen affinity purification to enhance specificity. The antibody is preserved in a storage buffer containing 0.03% Proclin 300, 50% Glycerol, and 0.01M PBS at pH 7.4, which helps maintain stability during storage. The product is specifically reactive with K. lactis strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37 (also known as Candida sphaerica) and has been validated for applications including ELISA and Western Blot .

What validation applications has LAC9 Antibody been tested for?

LAC9 Antibody has been specifically validated for two primary applications: Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB). These validation tests confirm the antibody's ability to recognize and bind to the LAC9 protein under the specific conditions used in these techniques. ELISA applications typically involve the antibody binding to immobilized LAC9 protein in a microplate format, while Western Blot applications involve detecting the protein after separation by gel electrophoresis and transfer to a membrane. The manufacturer emphasizes the importance of ensuring proper identification of the antigen in each application to confirm specificity. It's important to note that while these are the validated applications, researchers may need to optimize conditions for their specific experimental systems, and additional applications beyond ELISA and WB would require further validation by the end-user .

How should researchers validate LAC9 Antibody specificity for yeast experiments?

Validating LAC9 Antibody specificity is crucial for generating reliable experimental data. Based on established antibody validation frameworks, researchers should implement multiple complementary approaches to confirm LAC9 Antibody specificity in yeast systems:

• Genetic validation: Utilize LAC9 knockout or knockdown K. lactis strains as negative controls. The absence of signal in these genetic models provides strong evidence of antibody specificity .

• Orthogonal strategy: Compare antibody-based detection results with alternative methods such as RT-PCR for LAC9 mRNA or mass spectrometry-based protein identification to verify consistent detection patterns .

• Multiple antibody approach: If available, use different antibodies targeting distinct epitopes of LAC9 protein and compare detection patterns. Consistent results across different antibodies strengthen confidence in specificity .

• Recombinant expression: Test the antibody against samples with controlled overexpression of LAC9 protein, which should show corresponding signal increases if the antibody is specific .

• Cross-reactivity assessment: Evaluate potential cross-reactivity by testing the antibody against related yeast species or strains to confirm specificity for K. lactis LAC9 .

Each validation method addresses different aspects of antibody specificity, and researchers should document all validation experiments comprehensively, including positive and negative controls. The "five pillars" approach to antibody validation recommends using at least two independent methods to establish specificity before proceeding with experimental applications .

What are optimal Western Blot protocols for LAC9 Antibody?

Optimizing Western Blot protocols for LAC9 Antibody requires systematic consideration of multiple experimental parameters to ensure specific and sensitive detection of LAC9 protein. The following methodological approach is recommended:

• Sample preparation: Lyse K. lactis cells using a buffer containing protease inhibitors (e.g., PMSF, aprotinin, leupeptin) to prevent protein degradation. For yeast cells, mechanical disruption methods such as glass bead homogenization may be necessary to ensure efficient lysis of the cell wall.

• Protein separation: Load 20-40 μg of total protein per lane on SDS-PAGE gels (typically 10-12% acrylamide) for optimal resolution of LAC9 protein.

• Transfer conditions: Transfer proteins to PVDF or nitrocellulose membranes using standard transfer buffers (25 mM Tris, 192 mM glycine, 20% methanol) at 100V for 60-90 minutes or 30V overnight at 4°C.

• Blocking step: Block nonspecific binding sites using 5% non-fat dry milk or BSA in TBS-T (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute LAC9 Antibody at 1:500 to 1:2000 in blocking buffer and incubate overnight at 4°C with gentle agitation. The optimal dilution should be determined empirically.

• Washing steps: Wash the membrane thoroughly (3-5 times for 5-10 minutes each) with TBS-T to remove unbound antibody.

• Secondary antibody: Incubate with HRP-conjugated anti-rabbit IgG (typically at 1:5000 dilution) for 1 hour at room temperature.

• Detection system: Develop using enhanced chemiluminescence (ECL) reagents with exposure times optimized based on signal strength.

• Controls: Always include positive controls (recombinant LAC9 protein or wild-type K. lactis lysate) and negative controls (LAC9 knockout strain lysate if available) .

Optimization may be required for each new batch of antibody and for different sample types. Documenting successful protocol parameters is essential for reproducibility in subsequent experiments.

How can researchers troubleshoot unexpected results with LAC9 Antibody?

When LAC9 Antibody yields unexpected results, researchers should systematically investigate multiple factors that could impact antibody performance. This structured troubleshooting approach helps identify and resolve experimental issues:

• Antibody integrity assessment:

  • Verify proper storage conditions (-20°C or -80°C) and check for visible precipitates

  • Confirm antibody hasn't exceeded its shelf life

  • Minimize freeze-thaw cycles which can degrade antibody performance

• Sample preparation evaluation:

  • Ensure complete lysis of yeast cells (which have rigid cell walls)

  • Verify protein integrity by examining total protein patterns on stained gels

  • Confirm proper handling of samples to prevent protein degradation

  • Check protein quantification accuracy for consistent loading

• Protocol optimization:

  • Adjust antibody concentration (try serial dilutions from 1:250 to 1:2000)

  • Modify blocking conditions (test alternative blocking agents like BSA vs. milk)

  • Extend primary antibody incubation time (overnight at 4°C often improves results)

  • Increase washing stringency to reduce background signals

• Epitope accessibility considerations:

  • Test different sample preparation methods that may affect protein conformation

  • Consider whether post-translational modifications might mask the epitope

  • Try denaturing vs. non-denaturing conditions depending on epitope characteristics

• Experimental controls:

  • Include positive controls (recombinant LAC9 protein)

  • Use negative controls (non-expressing samples or immunoglobulin isotype controls)

  • Consider genetic validation with LAC9 knockout strains when available

• Cross-reactivity investigation:

  • Test for potential cross-reactivity with similar proteins

  • Verify the yeast strain matches the antibody's validated target species

Each troubleshooting step should be documented systematically, changing only one variable at a time to identify the source of unexpected results.

What considerations are important when using LAC9 Antibody for co-immunoprecipitation studies?

When using LAC9 Antibody for co-immunoprecipitation (co-IP) to study LAC9 protein interactions, researchers must address several methodological considerations to ensure successful results:

• Lysis buffer selection:

  • Use gentle, non-denaturing buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40) to preserve protein-protein interactions

  • Include protease inhibitors freshly before use to prevent degradation

  • Consider low concentrations of detergents (0.1-0.5%) that solubilize membranes without disrupting protein complexes

• Antibody binding optimization:

  • Pre-clear lysates with Protein A/G beads to reduce non-specific binding

  • Use 2-5 μg of LAC9 Antibody per mg of total protein

  • Optimize antibody incubation time (4-16 hours at 4°C) with gentle rotation

  • Consider pre-coupling antibody to beads before adding lysate

• Washing protocol development:

  • Design a washing strategy with decreasing stringency (high salt to low salt)

  • Typically use 3-5 washes with buffers containing 0.1-0.5% detergent

  • Balance between removing non-specific interactions while preserving specific ones

  • Consider including competitors for non-specific interactions in wash buffers

• Elution method selection:

  • Choose between native elution (using excess antigen) versus denaturing elution (SDS buffer)

  • For MS-based identification of interactors, denaturing elution often provides better recovery

  • Consider on-bead digestion approaches for sensitive proteomic analysis

• Critical controls:

  • Include IgG control immunoprecipitations to identify non-specific binding

  • Use input samples (5-10% of starting material) for comparison

  • When possible, include genetic controls (LAC9 knockout strains)

The success of co-IP experiments depends significantly on maintaining native protein conformations and interactions throughout the procedure while minimizing non-specific binding that can lead to false positive results.

How does the antibody-based detection of LAC9 compare with other research methodologies?

LAC9 Antibody offers specific advantages and limitations compared to alternative approaches for studying LAC9 protein function in K. lactis:

For comprehensive studies of LAC9 function, researchers should consider combining antibody-based detection with complementary approaches. For instance, using LAC9 Antibody for protein detection via Western blot while employing ChIP-seq to map LAC9 binding sites would provide both protein expression data and functional insights into transcriptional regulation .

The choice of methodology should be guided by the specific research questions being addressed, with LAC9 Antibody being particularly valuable for direct detection of the native protein in wild-type strains without genetic manipulation requirements.

What validation standards should be applied to LAC9 Antibody before use in critical experiments?

Before employing LAC9 Antibody in critical experiments, researchers should implement a comprehensive validation strategy based on established standards in the field. The International Working Group for Antibody Validation has developed the "five pillars" framework that provides a systematic approach to antibody validation applicable to LAC9 Antibody:

• Genetic validation: Test the antibody in LAC9 knockout or knockdown yeast strains. The absence of signal in these negative controls provides compelling evidence of specificity. This approach is particularly powerful as it directly tests the antibody against samples lacking only the target protein .

• Orthogonal validation: Compare LAC9 protein detection using the antibody with an antibody-independent method such as targeted mass spectrometry or RNA expression analysis (accounting for potential post-transcriptional differences). Correlation between methods strengthens confidence in the antibody's specificity .

• Independent antibody validation: If available, use multiple antibodies targeting different epitopes of LAC9 protein. Consistent detection patterns across different antibodies provide strong evidence of specificity. This approach is especially valuable when genetic models are unavailable .

• Expression validation: Test the antibody in systems with experimentally induced variation in LAC9 expression levels (e.g., using inducible promoters). The antibody signal should correspond proportionally to expression levels .

• Immunoprecipitation-mass spectrometry: Perform immunoprecipitation using the LAC9 Antibody followed by mass spectrometry analysis to confirm capture of the intended target protein and identify potential cross-reactivities .

Researchers should document all validation experiments thoroughly, including both positive and negative results, and update validation as experimental conditions change. The validation data should be specific to each application (Western blot, ELISA, etc.) as antibody performance can vary significantly between applications .

How does LAC9 Antibody quality impact reproducibility in yeast research?

The quality of LAC9 Antibody significantly impacts experimental reproducibility in yeast research through multiple mechanisms that influence data reliability:

• Batch-to-batch variability: Polyclonal antibodies like LAC9 Antibody may exhibit variation between production lots due to differences in immunized animals, immunization responses, and purification processes. This variability can manifest as differences in specificity, affinity, and background signals. Researchers should record lot numbers and test new lots against previous ones before use in critical experiments .

• Specificity limitations: Insufficient characterization of LAC9 Antibody may lead to undetected cross-reactivity with related proteins in K. lactis or other yeast species. This issue is particularly problematic in comparative studies across strains or species, where differential expression of cross-reactive proteins can be misinterpreted as changes in LAC9 expression .

• Documentation inadequacies: The "antibody characterization crisis" has revealed that approximately 50% of commercial antibodies fail to meet basic standards for characterization, contributing to an estimated $0.4-1.8 billion in annual financial losses from irreproducible research in the United States alone. Even well-characterized antibodies require validation in each specific experimental context .

• Context-dependent performance: LAC9 Antibody performance can vary based on experimental conditions, sample preparation methods, and detection systems. Standardized protocols with detailed documentation of all parameters are essential for reproducibility .

• Recombinant alternatives: While the current LAC9 Antibody is a polyclonal preparation, the field is increasingly moving toward recombinant antibodies, which offer greater consistency between batches. Studies have demonstrated that recombinant antibodies are typically more effective and reproducible than polyclonal antibodies, especially when validated using knockout cell lines .

To enhance reproducibility, researchers should thoroughly document antibody information (supplier, catalog number, lot number, dilution), validation methods, and detailed experimental protocols in publications and laboratory records.

What factors should guide experimental design when using LAC9 Antibody for detecting post-translational modifications?

When designing experiments to detect post-translational modifications (PTMs) of LAC9 protein using LAC9 Antibody, researchers should consider several critical factors:

• Epitope accessibility assessment:

  • Determine whether the LAC9 Antibody's epitope overlaps with potential PTM sites

  • If the antibody was raised against a recombinant protein lacking PTMs, it may have reduced affinity for modified forms

  • Consider using phospho-specific or other PTM-specific antibodies alongside general LAC9 Antibody

• Sample preparation optimization:

  • Include appropriate phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) or other PTM-preserving reagents in lysis buffers

  • Minimize time between sample collection and processing to prevent PTM loss

  • Consider using specialized lysis buffers optimized for preserving specific PTMs

• Enrichment strategies:

  • Implement immunoprecipitation using LAC9 Antibody before PTM analysis

  • Consider PTM-specific enrichment techniques (e.g., titanium dioxide for phosphopeptides)

  • Use fractionation methods to concentrate low-abundance modified forms

• Detection methods selection:

  • For phosphorylation: Use Phos-tag gels or mobility shift assays to separate phosphorylated forms

  • For ubiquitination/SUMOylation: Consider using denaturing conditions to preserve these modifications

  • For glycosylation: Evaluate lectin-based detection methods in parallel with antibody detection

• Validation approaches:

  • Treat samples with specific enzymes (phosphatases, deubiquitinases, etc.) as controls

  • Compare wild-type LAC9 with mutant forms where potential PTM sites are altered

  • Use mass spectrometry as an orthogonal approach to verify PTM identification

• Controls design:

  • Include samples where PTMs are induced or blocked through specific treatments

  • Use genetic models with mutations at predicted PTM sites

  • Consider the timing of sample collection, as many PTMs are dynamically regulated

The experimental design should acknowledge that different PTMs may require distinct approaches, and that LAC9 Antibody may have variable affinity for differently modified forms of the protein.

How can LAC9 Antibody be integrated into multi-omics approaches for yeast systems biology?

Integrating LAC9 Antibody into multi-omics research frameworks provides valuable protein-level data that complements other omics approaches for comprehensive systems biology studies in yeast:

• Integration with transcriptomics:

  • Use LAC9 Antibody detection via Western blot to correlate protein levels with LAC9 mRNA expression data

  • Identify post-transcriptional regulation mechanisms by examining discrepancies between transcript and protein levels

  • Time-course experiments can reveal temporal relationships between transcription and protein expression

• Combination with proteomics:

  • Employ LAC9 Antibody for targeted verification of mass spectrometry-based proteomics data

  • Use immunoprecipitation with LAC9 Antibody followed by mass spectrometry to identify interaction partners

  • Enrichment of low-abundance LAC9 protein using the antibody can improve detection sensitivity in complex samples

• Connection to genomics/epigenomics:

  • Apply chromatin immunoprecipitation (ChIP) using LAC9 Antibody followed by sequencing (ChIP-seq) to map genome-wide binding sites

  • Correlate LAC9 binding patterns with epigenetic marks and chromatin accessibility data

  • Use genetic variants (natural or engineered) to study impacts on LAC9 protein levels and function

• Relation to metabolomics:

  • Monitor changes in LAC9 protein levels or modifications in response to metabolic perturbations

  • Correlate metabolic pathway activities with LAC9-mediated transcriptional regulation

  • Study the impact of nutrient availability on LAC9 protein expression and localization

• Data integration frameworks:

  • Develop computational models incorporating LAC9 protein data with other omics layers

  • Use network analysis to position LAC9 within regulatory networks

  • Apply machine learning approaches to predict LAC9 activity based on multi-omics signatures

• Technological considerations:

  • Standardize sample processing across omics platforms to ensure data comparability

  • Implement consistent experimental designs with appropriate time points for capturing dynamic processes

  • Consider single-cell approaches when heterogeneity is expected in the yeast population

This integrated approach places LAC9 protein data within the broader context of cellular regulation, providing a more comprehensive understanding of transcriptional networks in K. lactis.

What are the future directions for LAC9 Antibody applications in yeast research?

The future of LAC9 Antibody applications in yeast research is likely to evolve along several methodological and technological trajectories that will expand its utility and reliability:

• Transition to recombinant antibody technology: The field is moving toward recombinant antibody formats that offer superior reproducibility compared to polyclonal antibodies. Future LAC9 antibodies will likely be available as recombinant versions with published sequence information, enabling better reproducibility across laboratories and experimental setups .

• Integration with advanced microscopy techniques: LAC9 Antibody applications will expand into super-resolution microscopy and other advanced imaging approaches to study the spatial organization of LAC9 protein within yeast cells at unprecedented resolution. This will provide insights into nuclear localization patterns and potential association with specific chromatin domains .

• Development of LAC9 biosensors: Modified versions of LAC9 antibodies may be engineered into biosensors for real-time monitoring of LAC9 protein dynamics in living cells, potentially through the development of intrabodies or nanobodies that function in the intracellular environment .

• Expansion of cross-species applications: As more comprehensive validation is performed, LAC9 Antibody may find broader applications in comparative studies across multiple yeast species to understand the evolution of transcriptional regulation mechanisms .

• Application in synthetic biology: LAC9 Antibody will likely become an important tool in synthetic biology approaches that use K. lactis as a platform organism, enabling researchers to monitor and validate engineered transcriptional circuits .

• Advancement in multiplexed detection systems: Future applications will likely incorporate LAC9 Antibody into multiplexed detection platforms that simultaneously monitor multiple transcription factors and their modifications, providing a systems-level view of transcriptional regulation .

• Enhancement of validation standards: As antibody characterization becomes increasingly rigorous, future LAC9 Antibody products will come with more comprehensive validation data, potentially including results from genetic knockout models and cross-reactivity profiles across related proteins .